Sterling Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Sterling Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.4K	Sell	71 -512	-88%	-$121K	﹤0.01%	1839
2026 Q1	$116K	Sell	583 -421	-42%	-$83.3K	﹤0.01%	1344
2025 Q4	$190K	Sell	1,004 -171	-15%	-$32.9K	﹤0.01%	1329
2025 Q3	$208K	Buy	1,175 +714	+155%	+$106K	﹤0.01%	1308
2025 Q2	$52.4K	Buy	461 +152	+49%	+$16.2K	﹤0.01%	1491
2025 Q1	$32.5K	Sell	309 -237	-43%	-$26.8K	﹤0.01%	1531
2024 Q4	$58.5K	Buy	546 +487	+825%	+$55.1K	﹤0.01%	1572
2024 Q3	$5.91K	Buy	+59	New	+$5.94K	﹤0.01%	1698

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's LGND Position: Q2 2026 in Review

Sterling Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 88% in Q2 2026, selling an estimated $121K and leaving 71 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1839.

Sterling Capital Management first reported a position in LGND in Q3 2024 and has held it in 8 quarters since. The position peaked at $208K in Q3 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Sterling Capital Management held 71 shares of Ligand Pharmaceuticals worth $22.4K as of Q2 2026.
Sterling Capital Management sold 512 Ligand Pharmaceuticals shares in Q2 2026, an estimated $121K.
Ligand Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1839 holding.
Sterling Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Ligand Pharmaceuticals position peaked at $208K in Q3 2025.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.